0001387131-22-002105.txt : 20220217 0001387131-22-002105.hdr.sgml : 20220217 20220217171716 ACCESSION NUMBER: 0001387131-22-002105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220215 FILED AS OF DATE: 20220217 DATE AS OF CHANGE: 20220217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEDERMAN SETH CENTRAL INDEX KEY: 0001563420 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 22649389 MAIL ADDRESS: STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP STREET 2: 509 MADISON AVE., SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 4 1 lederman-form4_021522.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP X0306 4 2022-02-15 0 0001430306 Tonix Pharmaceuticals Holding Corp. TNXP 0001563420 LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 1 1 0 0 Chief Executive Officer Stock Option 0.207 2022-02-15 4 A 0 5000000 0.00 A 2023-02-15 2032-02-15 Common Stock 5000000 5000000 D Stock Option 0.414 2022-02-15 4 A 0 5000000 0.00 A 2023-02-15 2032-02-15 Common Stock 5000000 5000000 D Stock Option 0.621 2022-02-15 4 A 0 5000000 0.00 A 2023-02-15 2032-02-15 Common Stock 5000000 5000000 D Stock Option 0.828 2022-02-15 4 A 0 5000000 0.00 A 2023-02-15 2032-02-15 Common Stock 5000000 5000000 D One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. /s/ Seth Lederman 2022-02-17